Traws Pharma, Inc. (NASDAQ:TRAW – Get Free Report) was down 0.1% during trading on Friday . The company traded as low as $8.47 and last traded at $8.66. Approximately 180,366 shares changed hands during mid-day trading, a decline of 22% from the average daily volume of 231,983 shares. The stock had previously closed at $8.67.
Traws Pharma Stock Performance
The business has a 50 day moving average price of $5.99. The company has a market capitalization of $26.21 million, a P/E ratio of -0.06 and a beta of 1.46.
About Traws Pharma
Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.
Further Reading
- Five stocks we like better than Traws Pharma
- Most Volatile Stocks, What Investors Need to Know
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- Compound Interest and Why It Matters When Investing
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- What is the MACD Indicator and How to Use it in Your Trading
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
